Reducing unnecessary MRSA treatment in pneumonia patients using nasal screening
Rapid De-escalation of Anti-MRSA Therapy Guided by S. Aureus Nares Screening in Case of Pneumonia (SNAP Study)
This study is testing if using a nasal test for MRSA can help doctors quickly reduce unnecessary antibiotic treatment in pneumonia patients to improve their recovery and lower side effects.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 76 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Bari Aldo Moro Academic / other |
| Locations | 1 site (Bari) |
| Trial ID | NCT06238297 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of a nasal PCR-assay for MRSA in guiding the rapid de-escalation of anti-MRSA therapy in hospitalized patients with pneumonia. By utilizing this diagnostic tool, the study seeks to minimize the duration of unnecessary antibiotic treatment, which can lead to adverse effects and increased healthcare costs. The primary focus is on patients diagnosed with community-acquired, hospital-acquired, or ventilator-associated pneumonia, and the study will measure outcomes such as in-hospital mortality, length of stay, and incidence of adverse drug events. Enrollment occurs within 48 hours of starting empirical anti-MRSA therapy.
Who should consider this trial
Good fit: Ideal candidates include hospitalized patients aged 18 and older diagnosed with pneumonia who are starting empirical anti-MRSA therapy.
Not a fit: Patients with febrile neutropenia, severe immunodeficiency, chronic airway infections, or those suspected of having extrapulmonary MRSA infections may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce unnecessary antibiotic use and its associated complications in pneumonia patients.
How similar studies have performed: Other studies have shown promising results using similar diagnostic approaches for antibiotic stewardship, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects 18 years or older. * Patients hospitalized at the Azienda Consorziale Policlinico di Bari; * Clinical diagnosis of CAP/HAP/VAP; * Commitment by the prescribing physician to set an anti-MRSA antibiotic therapy in empirical * Enrollement within 48h from the beginning of the empirical anti-MRSA therapy. Exclusion Criteria: * Febrile neutropenia or severe immunodeficiency; * Chronic airway infection (eg cystic fibrosis); * Suspect of extrapulmonary infection by MRSA * Refusal by the patient or legal guardian; * Refusal by the physician in charge of the patient to perform antibiotic de-escalation based on the result of the nasal swab; * Enrollment after 48 hours from the beginning of the empirical anti-MRSA therapy.
Where this trial is running
Bari
- Università di Bari "Aldo Moro" — Bari, Italy (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.